

## **Clinical Policy: RimabotulinumtoxinB (Myobloc)**

Reference Number: CP.PHAR.233

Effective Date: 07.01.16

Last Review Date: 05.21

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

RimabotulinumtoxinB (Myobloc<sup>®</sup>) is an acetylcholine release inhibitor and a neuromuscular blocking agent.

### **FDA Approved Indication(s)**

Myobloc is indicated for the treatment of :

- Adults with cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD
- Adults with chronic sialorrhea

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Myobloc is **medically necessary** when one of the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Cervical Dystonia (*focal dystonia*) (must meet all):**

1. Diagnosis of CD;
2. Prescribed by or in consultation with a neurologist, orthopedist, or physiatrist;
3. Age  $\geq$  18 years;
4. Member is experiencing involuntary contractions of the neck and shoulder muscles (e.g., splenius capitis, sternocleidomastoid, levator scapulae, scalene, trapezius, semispinalis capitis) resulting in abnormal postures or movements of the neck, shoulders or head;
5. Contractions are causing pain and functional impairment;
6. Failure of Xeomin<sup>®</sup> and Dysport<sup>®</sup>, unless clinically significant adverse effects are experienced or both are contraindicated;
7. Member meets both of the following (a and b):
  - a. Myobloc is not prescribed concurrently with other botulinum toxin products;
  - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
8. Treatment plan provided detailing number of Units per indication and treatment session;
9. Dose does not exceed 5,000 Units per treatment session.

##### **Approval duration:**

**Medicaid** – 12 weeks (single treatment session)

**Commercial** – 6 months

**B. Chronic Sialorrhea** (must meet all):

1. Diagnosis of chronic sialorrhea for at least the last three months due to one of the following (a or b):
  - a. Underlying neurologic disorder (e.g., Parkinson disease, atypical parkinsonism, stroke, traumatic brain injury, cerebral palsy, amyotrophic lateral sclerosis);
  - b. Craniofacial abnormality (e.g., Goldenhar syndrome);
2. Prescribed by or in consultation with a neurologist or physiatrist;
3. Age  $\geq$  18 years;
4. Failure of at least one anticholinergic drug (*see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated;
5. Failure of Xeomin, unless contraindicated or clinically significant adverse effects are experienced;
6. Member meets both of the following (a and b):
  - a. Myobloc is not prescribed concurrently with other botulinum toxin products;
  - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
7. Treatment plan provided detailing number of Units per indication and treatment session;
8. Dose does not exceed 1,500 Units per parotid gland, 250 Units per submandibular gland, 3,500 units per treatment session.

**Approval duration:**

**Medicaid/HIM** – 12 weeks (single treatment session)

**Commercial** – 6 months

**C. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial , HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Approval**

**A. Cervical Dystonia** (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Member meets both of the following (a and b):
  - a. Myobloc is not prescribed concurrently with other botulinum toxin products;
  - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
4. Treatment plan provided detailing number of Units per indication and treatment session;
5. If request is for a dose increase, new dose does not exceed 10,000 Units per treatment session.

**Approval duration:**

**Medicaid** – 12 weeks (single treatment session)

**Commercial** – 12 months

**B. Chronic Sialorrhea (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Member meets both of the following (a and b):
  - a. Myobloc is not prescribed concurrently with other botulinum toxin products;
  - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
4. Treatment plan provided detailing number of Units per indication and treatment session;
5. If request is for a dose increase, dose does not exceed 1,500 Units per parotid gland, 250 Units per submandibular gland, 3,500 Units per treatment session.

**Approval duration:**

**Medicaid** – 12 weeks (single treatment session)

**Commercial** – 12 months

**C. Other diagnoses/indications (1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy;

**Approval duration: 12 weeks (single treatment session);** or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid;
- B.** Cosmetic treatment of hyperfunctional wrinkles of the upper face including glabellar frown lines, deep forehead wrinkles and periorbital wrinkles (crow's feet);
- C.** For Ambetter, hyperhidrosis is a benefit exclusion categorized as a cosmetic service;
- D.** Same-visit treatment of multiple indications.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CD: cervical dystonia

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

| Drug Name                                    | Dosing Regimen  | Dose Limit/<br>Maximum Dose |
|--|---|-----------------------------|
| glycopyrrolate (Glycate <sup>®</sup> )       | Chronic Sialorrhea:<br>1 mg PO TID  | 6 mg/day                    |
| benztropine (Cogentin <sup>®</sup> )         | Chronic Sialorrhea:<br>1 mg PO QD-BID   | 3.8 mg/day                  |
| Xeomin <sup>®</sup><br>(incobotulinumtoxinA) | Chronic Sialorrhea:<br>Up to 30 Units IM per parotid gland, 20 Units IM per submandibular gland, and 100 Units IM per treatment session every 16 weeks. | 100 Units/16 weeks          |
| Dysport <sup>®</sup> (abobotulinumtoxin A)   | Cervical Dystonia:<br>Divided among affected muscles every 12 weeks: Up to 1,000 Units IM   | See dosing regimen          |
| Xeomin <sup>®</sup><br>(incobotulinumtoxinA) | Cervical Dystonia:<br>Up to 120 Units IM per treatment session every 12 weeks.  | 300 Units/12 weeks          |

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications and Boxed Warnings*

- Contraindication(s):
  - Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation
  - Infection at the proposed injection site
- Boxed warning(s): distant spread of toxin effect

*Appendix D: Botulinum Toxin Product Interchangeability*

- Potency Units of Myobloc are not interchangeable with other botulinum toxin product preparations (e.g., Dysport<sup>®</sup>, Botox<sup>®</sup>, Xeomin<sup>®</sup>).

**V. Dosage and Administration**

| Indication         | Dosing Regimen  | Maximum Dose          |
|--------------------|---|-----------------------|
| CD                 | Divided among affected muscles every 12 weeks: <ul style="list-style-type: none"> <li>• Initial dose: Up to 5,000 Units IM</li> <li>• Subsequent dose: Up to 10,000 Units IM</li> </ul> | 10,000 Units/12 weeks |
| Chronic sialorrhea | Up to 1,500 Units IM per parotid gland, 250 Units IM per submandibular gland, and 3,500 Units IM per treatment session every 12 weeks.  | 3,500 Units/12 weeks  |

**VI. Product Availability**

Vial: 2,500 Units/0.5 mL, 5,000 Units/1 mL, 10,000 Units/2 mL

**VII. References**

1. Myobloc Prescribing Information. Louisville, KY: Solstice Neurosciences, Inc.; August 2019. Available at [https://myobloc.com/files/MYOBLOC\\_PL.pdf](https://myobloc.com/files/MYOBLOC_PL.pdf). Accessed February 28, 2021.
2. OnabotulinumtoxinA. In: Micromedex. Ann Arbor, MI: Truven Health Analytics; 2020. Available from: [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Accessed February 17, 2020.

*Dystonia*

3. Simpson DM, Hallett M, Ashman EJ et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016; 86(19): 1818-1826.
4. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. *Mov Disord*. June 15, 2013; 28(7): 863-873. doi:10.1002/mds.25475.
5. Cloud LJ, Jinnah HA. Treatment strategies for dystonia. *Expert Opin Pharmacother* 2010; 11(1):5-15.

*Sialorrhea*

6. Seppi K, Chahine L, Chaudhuri R et al. International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the non-motor symptoms of Parkinson’s Disease. 2018. Available at <https://www.movementdisorders.org/MDS-Files1/Resources/PDFs/EBM-NMS-Final-Paper-August-2018.pdf>.
7. Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials. *Journal of Clinical Neuroscience* 51 (2018) 12–17.
8. Lakraj AA, Moghimi, Jabbari B. Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins* 2013, 5, 1010-1031; doi:10.3390/toxins5051010.
9. Young CA, Johnson EC, et al. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. *Cochrane Database Syst Rev*. 2011 May 11;(5):CD006981. doi: 10.1002/14651858.CD006981.pub2.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Codes | Description                               |
|-------------|---|
| J0587       | Injection, rimabotulinumtoxinB, 100 units |

| Reviews, Revisions, and Approvals   | Date     | P&T Approval Date |
|---|----------|-------------------|
| <p>Added definition and requirement of pain and functional impairment to CD.<br/>Added examples of muscle groups and an informational footnote to upper limb spasticity. Efficacy statement added under continuation criteria. Safety information removed. Dystonia information is added at Appendix B. “Non-cosmetic” parenthetical added to the background FDA indication section; cosmetic coverage restriction reworded under the “Other Diagnoses/Indications” section to include notation of glabellar lines.</p> | 06.17    | 07.17             |
| <p>2Q 2018 annual review: added physical medicine and rehabilitation specialist for cervical dystonia; combined Medicaid and Commercial lines of business; added HIM; Commercial: approval durations changed from length of benefit to 6 months initial and 12 months continued approval; references reviewed and updated.</p>  | 04.24.18 | 05.18             |
| <p>HIM removed as Myobloc does not require prior authorization for this line of business</p>  | 05.29.18 |                   |
| <p>2Q 2019 annual review: added HIM-Medical Benefit line of business; no significant changes; references reviewed and updated.</p>  | 02.05.19 | 05.19             |
| <p>Criteria added for new FDA indication: chronic sialorrhea; added in Section III that for Ambetter, hyperhidrosis is a benefit exclusion categorized as a cosmetic service; references reviewed and updated.</p>  | 10.08.19 | 02.20             |
| <p>2Q 2020 annual review: rehabilitation specialist incorporated under physiatrist; previous (last 12 weeks) or concurrent toxin product use restriction added to all initial/continuation criteria; dosing updated per package insert; same-visit treatment for multiple indications is excluded (Section III); references reviewed and updated.</p>   | 03.02.20 | 05.20             |
| <p>Per October SDC and prior clinical guidance, added the following redirections: Xeomin and Dysport for cervical dystonia, Xeomin for chronic sialorrhea.</p>  | 10.08.20 |                   |
| <p>2Q 2021 annual review: no significant changes; treatment plan requirement detailing number of Units per site and treatment session is changed to per indication and treatment session; revised HIM-Medical Benefit to HIM line of business; references reviewed and updated.</p>   | 03.04.21 | 05.21             |
| <p>Ad Hoc update: max dose for Xeomin in Appendix B updated to 300 mg for CD per PI.</p>  | 07.26.21 |                   |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional

organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.



©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.